Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133927 | 0.83 | PPARG (0.56) | CA2SLC6A2 | |
| SCHEMBL1566396 | 0.83 | CYP1A2 (0.61) | SLC7A5FOLH1 | |
| SCHEMBL7483692 | 0.83 | CYP1A2 (0.61) | SLC7A5FOLH1 | |
| SCHEMBL2397070 | 0.83 | CYP1A2 (0.61) | SLC7A5FOLH1 | |
| SCHEMBL7508594 | 0.82 | CPA1 (0.51) | CA2 | |
| SCHEMBL7510405 | 0.82 | CPA1 (0.51) | CA2 | |
| Hydrochloric Acid SCHEMBL6054521 | 0.81 | CYP1A2 (0.59) | SLC7A5FOLH1 | |
| SCHEMBL490650 | 0.80 | SLC7A5 (0.67) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL14314182 | 0.79 | ESR1 (0.47) | SLC7A5CA2CAMK2AESR1ESR2 | |
| SCHEMBL10436391 | 0.78 | CYP1A2 (0.68) | SLC7A5CA2CAMK2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999095-A2 | PROCESSES FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-ACETOXYSTYRENE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7402713-B2 | Processes for conversion of tyrosine to p-hydroxystyrene and p-acetoxystyrene | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-22 | — | — | US | disclosed |
| WO-2008085512-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167493-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-07-10 | — | — | US | disclosed |
| WO-2007103478-A2 | PROCESSES FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-ACETOXYSTYRENE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213569-A1 | Processes for conversion of tyrosine to p-hydroxystyrene and p-acetoxystyrene | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213569-A1 | Processes for conversion of tyrosine to p-hydroxystyrene and p-acetoxystyrene | TH, PAH, TPST2 | SLC7A5 3262/4885CA2 2621/4885CAMK2A 1693/4885 |
| US-20080167493-A1 | METHODS FOR CONVERSION OF TYROSINE TO P-HYDROXYSTYRENE AND P-HYDROXYCINNAMIC ACID | TH, HPD, PAH | SLC7A5 771/4885CA2 2294/4885CAMK2A 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.